Phase 1 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with an advanced or metastatic solid tumour (a cancer that has spread) who have already tried standard treatments that did not work, or whose cancer has come back after prior treatment
• People with a good general level of physical functioning (an ECOG performance score of 0 or 1, meaning mostly active and able to carry out daily activities — confirm with trial site)
• People with a life expectancy of at least 3 months
• People whose blood, liver, and kidney functions are at adequate levels as assessed by the trial site
• People who are willing to provide an existing tumour tissue sample or biopsy report, or who are willing to have a new tumour biopsy taken, and who agree to provide blood samples during the study
• Women who could become pregnant must have a negative pregnancy blood test taken 28 days before the first dose
• Both men and women who could become pregnant must agree to use effective contraception throughout the entire treatment period and for 2 months after treatment ends
• People who understand and are willing to sign an informed consent form, and who are able to attend all required study visits and complete study-related tasks

Who may not be able to join:

• People who have a known allergy to any ingredient in the study drug
• People who have a history of another separate primary cancer
• People who still have side effects from a previous cancer treatment that have not improved to a mild level (Grade 1 or lower under standard medical grading — confirm with trial site)
• People who received anti-cancer treatments such as chemotherapy, biological therapies, immunotherapy, or targeted therapy within 28 days before the first dose, or radiation therapy within 14 days before the first dose
• People who used certain medications known to significantly affect how the liver processes drugs (P450 metabolism) within 2 weeks before the first dose
• People who participated in another clinical trial or took another experimental treatment within 28 days before the first dose
• People who had major surgery or a serious physical injury within 28 days before the first dose
• People who need to take medications known to affect the heart's electrical rhythm in a way that could cause a dangerous irregular heartbeat
• People with a history or current presence of certain health conditions, including: HIV, hepatitis B or C infection; blood clotting problems or use of blood-thinning medications; significant heart or cardiovascular disease; pneumonia; digestive conditions that could affect how the drug is absorbed; uncontrolled high blood pressure; ulcers in the stomach, intestines, throat, or oesophagus; uncontrolled seizures or other brain/nervous system conditions; poorly controlled diabetes; a heart rhythm condition called long QT syndrome; uncontrolled active infections; uncontrolled fluid build-up around the heart or in the abdomen; adrenal gland problems; thyroid problems; severe unhealed wounds, ulcers, or bone fractures; or a history of severe skin reactions (Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome)
• People with brain or spinal tumours (whether primary or spread from elsewhere) that are causing symptoms or are not controlled, or untreated conditions compressing the spinal cord
• Women who are pregnant or currently breastfeeding
• People who used immune-suppressing medications within 14 days before the first dose
• People who received a vaccine within 30 days before the start of the study
• People with any other condition or history that the trial investigators determine could affect study results or their ability to safely participate

Important: Always verify eligibility with the trial site directly before applying.